Possible mechanism of action in melatonin attenuation of haloperidol-induced orofacial dyskinesia

Pharmacology, Biochemistry, and Behavior
Pattipati S NaiduShrinivas K Kulkarni


Tardive dyskinesia (TD) is a late complication of prolonged neuroleptic treatment characterized by involuntary movements of the oral region. In spite of high incidence and much research, the pathophysiology of this devastating movement disorder remains elusive. Chronic treatment with neuroleptics leads to the development of abnormal oral movements in rats, referred to as vacuous chewing movements (VCMs). VCMs in rats are widely accepted as an animal model of TD. Rats chronically treated with haloperidol (1.5 mg/kg ip) significantly developed VCMs and tongue protrusions. Melatonin dose-dependently (1, 2, and 5 mg/kg) reversed the haloperidol-induced VCM and tongue protrusions frequencies. Biochemical analysis reveals that chronic haloperidol treatment significantly induced lipid peroxidation and decreased the forebrain glutathione (GSH) levels in the rats. Chronic haloperidol-treated rats also showed decreased levels of antioxidant defense enzymes, superoxide dismutase (SOD), and catalase. Coadministration of melatonin (1, 2, and 5 mg/kg) along with haloperidol significantly reduced the lipid peroxidation and restored the decreased GSH levels by chronic haloperidol treatment, and significantly reversed the haloperidol-induced de...Continue Reading


Jun 29, 1990·Biochemical and Biophysical Research Communications·V Ravindranath, D J Reed
May 1, 1995·Neurochemistry International·L R Barlow-WaldenB Poeggeler
Oct 29, 1993·Science·J T Coyle, P Puttfarcken
Jan 1, 1994·Life Sciences·C PieriF Marcheselli
May 1, 1993·Annals of Neurology·C BurkhardtW D Parker
May 1, 1993·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·J W Gorrod, J Fang
May 1, 1995·Journal of Pineal Research·C M CagnoliH Manev
Dec 1, 1995·Free Radical Biology & Medicine·E SewerynekR J Reiter
Dec 7, 1995·European Journal of Pharmacology·E SewerynekA Lewinski
Jan 1, 1997·Life Sciences·R J ReiterA Munoz-Hoyos
Nov 5, 1997·European Journal of Pharmacology·A E FleckensteinG R Hanson
Jan 1, 1997·Schizophrenia Bulletin·M F EganR J Wyatt
Mar 24, 1998·Journal of Pineal Research·M KotlerA Menéndez-Peláez
Oct 14, 1998·Progress in Neurobiology·R J Reiter
Mar 19, 1999·European Journal of Pharmacology·M VairettiF Bertè
Feb 10, 2000·Schizophrenia Bulletin·A M Elkashef, R J Wyatt
May 10, 2000·Free Radical Biology & Medicine·A M Lin, L T Ho
Sep 12, 2000·The Journal of Clinical Psychiatry·E ShamirA Weizman
Oct 18, 2000·Journal of Pineal Research·D BandyopadhyayR K Banerjee
Nov 9, 2000·Journal of Pineal Research·H J BrömmeD Peschke
Feb 24, 2001·Journal of Neural Transmission·R GaliliDaniel Offen
Nov 17, 2001·European Journal of Pharmacology·P S Naidu, Shrinivas K Kulkarni
Jan 10, 2002·European Journal of Pharmacology·P S Naidu, Shrinivas K Kulkarni
Jun 20, 2002·Psychopharmacology·V C AbílioR Frussa-Filho
May 1, 1959·Archives of Biochemistry and Biophysics·G L ELLMAN


May 16, 2009·Journal of Neural Transmission·Santhrani Thaakur, G Himabindhu
Sep 11, 2007·Bioscience Reports·Deepa S MaharajSanty Daya
Jun 7, 2005·Pharmacology, Biochemistry, and Behavior·Roselei FachinettoJoão B T Rocha
Jan 15, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Aoi SyuTadao Arinami
Aug 17, 2010·The International Journal of Neuroscience·Emiliano Ricardo Vasconcelos RiosMarta Maria de França Fonteles
Jun 17, 2006·International Review of Psychiatry·Krishna VaddadiJ L Waddington
Oct 13, 2009·General and Comparative Endocrinology·Márcio Alberto GeihsLuiz Eduardo Maia Nery
Dec 27, 2008·Pharmacology, Biochemistry, and Behavior·Angélica M TeixeiraMarilise Burger
Aug 19, 2014·Journal of Biomedical Materials Research. Part a·Engy R RashedMona A El-Ghazaly
Apr 20, 2010·Journal of Psychiatric Research·Da Chun ChenXiang Yang Zhang
May 23, 2013·Toxicology and Industrial Health·Mona A El-GhazalyAmal A Abd-El-Fattah
Mar 23, 2017·Canadian Journal of Physiology and Pharmacology·Dayane Pessoa de AraújoFausto Pierdoná Guzen
May 24, 2013·International Journal of Molecular Sciences·Armando L Morera-Fumero, Pedro Abreu-Gonzalez
Apr 13, 2007·Journal of Cellular Biochemistry·Santiago Ortega-GutiérrezR J Reiter
Dec 24, 2019·Free Radical Research·Gagan B N Chainy, Dipak Kumar Sahoo
Jan 21, 2009·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Savita G Bhakta, Chittaranjan Andrade
Jun 20, 2019·Current Protocols in Neuroscience·Fausto Pierdoná GuzenDayane Pessoa de Araújo
Aug 24, 2010·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·I-Ching LaiYing-Jay Liou
Jul 29, 2020·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Stewart A Factor

Related Concepts

Dose-Response Relationship, Drug
Dyskinesia, Medication-Induced
Free Radicals
Lipid Peroxidation
Rats, Wistar
Rats, Laboratory

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here